Journal article
Acrylamide and Glycidamide Hemoglobin Adducts and Epithelial Ovarian Cancer: A Nested Case-Control Study in Nonsmoking Postmenopausal Women from the EPIC Cohort
Mireia Obon-Santacana, Leila Lujan-Barroso, Ruth C Travis, Heinz Freisling, Pietro Ferrari, Gianluca Severi, Laura Baglietto, Marie-Christine Boutron-Ruault, Renee T Fortner, Jennifer Ose, Heiner Boeing, Virginia Menendez, Emilio Sanchez-Cantalejo, Saioa Chamosa, Jose Maria Huerta Castano, Eva Ardanaz, Kay-Tee Khaw, Nick Wareham, Melissa A Merritt, Marc J Gunter Show all
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | AMER ASSOC CANCER RESEARCH | Published : 2016
Abstract
BACKGROUND: Acrylamide was classified as "probably carcinogenic to humans (group 2A)" by the International Agency for Research on Cancer. Epithelial ovarian cancer (EOC) is the fourth cause of cancer mortality in women. Five epidemiological studies have evaluated the association between EOC risk and dietary acrylamide intake assessed using food frequency questionnaires, and one nested case-control study evaluated hemoglobin adducts of acrylamide (HbAA) and its metabolite glycidamide (HbGA) and EOC risk; the results of these studies were inconsistent. METHODS: A nested case-control study in nonsmoking postmenopausal women (334 cases, 417 controls) was conducted within the European Prospective..
View full abstractGrants
Awarded by Wereld Kanker Onderzoek Fonds (WCRF NL)
Awarded by Health Research Fund (FIS) of the Spanish Ministry of Health
Awarded by Regional Government of Murcia
Awarded by La Caixa
Awarded by Red Tematica de Investigacion Cooperativa en Cancer (Spain)
Awarded by Cancer Research UK
Awarded by Medical Research Council
Awarded by National Institute for Health Research
Funding Acknowledgements
This work was supported by the Wereld Kanker Onderzoek Fonds (WCRF NL; grant WCRF 2011/442) and by the Health Research Fund (FIS) of the Spanish Ministry of Health (Exp PI11/01473). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Health Research Fund (FIS) of the Spanish Ministry of Health, Regional Governments of Andalucia, Asturias, Basque Country, Murcia (no. 6236), Navarra and the Catalan Institute of Oncology, La Caixa (BM 06-130), Red Tematica de Investigacion Cooperativa en Cancer (RD12/0036/0018; RD06/0020/0091; Spain); Danish Cancer Society (Denmark); Ligue contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum (DKFZ) and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro (AIRC) and National Research Council (Italy); Dutch Ministry of Public Health, Welfare, and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF) and Statistics Netherlands (The Netherlands); Nordic Center of Excellence in Food, Nutrition, and Health-Helga (Norway); Swedish Cancer Society, Swedish Scientific Council and Regional Government of Skane and Vasterbotten (Sweden); Cancer Research UK (grant C570/A16491, R.C. Travis; grant 14136, K.T. Khaw, N.J. Wareham; United Kingdom); Medical Research Council (grant G1000143, K.T. Khaw, N.J. Wareham; grant MC_UU_12015/1, N.J. Wareham; United Kingdom). M. Obon-Santacana is affiliated with the University of Barcelona.